Deutsche Märkte geschlossen

Bioasis Technologies Inc. (BTI.V)

TSXV - TSXV Echtzeitpreis. Währung in CAD
Zur Watchlist hinzufügen
0,00500,0000 (0,00%)
Ab 03:52PM EDT. Markt geöffnet.

Bioasis Technologies Inc.

157 Church Street
19th floor
New Haven, CT 06510
United States

https://www.bioasis.us

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C.Executive Chairman, CEO & President208,8kN/A1958
Mr. David P. JenkinsChief Financial Officer125,28kN/A1962
Mr. Graeme DickDirector of Investor RelationsN/AN/AN/A
Mr. Aaron EltonDirector of MarketingN/AN/AN/A
Dr. Mei Mei TianVP & Head of External ResearchN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CAD.

Beschreibung

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

Corporate Governance

Bioasis Technologies Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.